Allergan, the makers of the Juvederm® family of facial dermal fillers, have 2 new fillers on the horizon for 2017. Both are temporary hyaluronic acid injectable fillers that use the patented Vycross™ technology from Allergan. Vycross™ technology allows for the Hylauronic Acid filler to be a soft and smooth product while combining blends of different molecular weights of hyaluronic acid. This blending of different molecular weights of hyaluronic acid contributes to the duration, or lasting effects, of the product. While both products contain Lidocaine to help minimize discomfort during treatment, the difference between Vollure and Volite is in the area that you treat and the expected outcomes of each product.
Dr. Chernoff will soon offer JUVÉDERM VOLLURE® XC (also known as Juvederm Volift in Europe). Allergan (makers of Botox, JUVÉDERM , JUVÉDERM VOLUMA and JUVÉDERM VOLBELLA) are expected to add the newest filler to their expanding U.S. aesthetic profile this Spring. It is in its final stages of FDA Approval.
Stay tuned for more information!
Join Our Juvederm® Vollure Waiting List